You are here



Eric Brouwer, PhD

Interim Chief Executive Officer and Chief Scientific Offcer

Eric has expertise in microfluidics, chemistry, antibodies and assay development in the point-of-care and infectious disease diagnostics sector. He brings a strong track record in leading innovative R&D organizations, technology assessment and implementing market-leading technologies in FDA and ISO-regulated environments.

Prior to joining SQI, Dr. Brouwer developed and launched a number of critical care point-of-care immunoassay products, working in Europe and in North America with Trinity Biotech plc as the Chief Scientific Officer. Prior to that, Dr Brouwer led product development at Abbott Point-of-Care. At Abbott, he was a member of the Scientific Governing Board and was the recipient of the Abbott Chairman's Award (2007) for the FDA 510(k) waiver clearance of a point-of-care Basic Metabolic test panel.

Dr. Brouwer received his BSc (Hons) from Queen’s University, MSc from the University of British Columbia and Ph.D. in Chemistry from Carleton University. He held a Post Doctoral Fellowship in Chemistry, at the University of Durham, UK.

Russell Peloquin

Vice President, Global Commercial Operations

Russell has spent many years in commercial management with biotechnology companies, leading high-level contract negotiations in the clinical diagnostics arena and working in the field of molecular multiplexing. A portfolio of international sales and business development experience includes commercializing a product with an international diagnostic startup that was subsequently acquired.

He previously oversaw the largest geography for the diagnostic business unit of a leading multiplexing technology company where he successfully created the market for and launched several molecular diagnostic assay products and automation systems that have become multi-million dollar revenue drivers. He was a nationally known leader for the world's largest clinical reference laboratory where his responsibilities included multi-million dollar contract negotiations, new laboratory equipment evaluation, sales and logistics management, and experience in M&A.

Russell leads SQI Diagnostics' business, strategy, sales, marketing, business development, customer solutions, field/technical support, and distributor and partner relations.

Morlan Reddock, MBA, CFA, CPA, CGA

Chief Financial Officer and VP of Administration

Morlan brings over 20 years of financial and strategic management experience to the leadership team.

His early career includes working as an equity research associate with Merrill Lynch Canada, an M&A consultant with PWC Canada’s Transaction Services team then progressive senior roles in Finance and Accounting with start-ups, turnarounds and established businesses including fortune 500 companies. His specialized skills include FP&A, M&A, Treasury and Investor Relations.

Morlan received his Bachelor of Engineering from Concordia University, MBA from the University of Toronto, Rotman School of Management, holds CFA and CPA, CGA designations and has completed leadership training at the Ivey School of Business.

Peter Lea, Ph.D.


Peter invented and patented the multiplexing microarray technology at the core of SQI Diagnostics. As such, he commercialized the world's first microarray diagnostic platform incorporating automation, calibration and normalization in each test well. His breakthrough is also the first to multiplex at the antigen and antibody subclass level.

He has been instrumental in managing the company’s IP portfolio, with four patents issued (and 15 pending) to support the complexity and uniqueness of the SQI Diagnostics multiplexing microarray system.

Prior to SQI Diagnostics, Peter was Director of Biophysics, then Director of Research and Development at Spectral Diagnostics, Inc., inventing and patenting cardiac diagnostics and new blood processing technology.

From 1970 through 1993, he was Director, Associate Laboratory Director, Investigator, and Research Associate Professor (Biophysics) at the Centres of Excellence: Canadian Genetic Diseases Network, Research Institute, Hospital for Sick Children, Faculty of Medicine, and University of Toronto.